The most extensively studied ImmTac molecule, tebentafusp (IMCgp100), an affinity enhanced TCR specific for a gp100 peptide (a melanocyte differentiation antigen) presented on HLA-A*02 complexes, has demonstrated clinical efficacy as a monotherapy against the gp100-positive uveal melanoma (214, 215). Here, PMEL is linked to uveal melanoma.